echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Nat Commun: The esodiol dosing trial revealed the relationship between progesterone-like and endocrine therapy responses in breast cancer patients

    Nat Commun: The esodiol dosing trial revealed the relationship between progesterone-like and endocrine therapy responses in breast cancer patients

    • Last Update: 2021-02-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    More than 70% of breast cancer patients are positive for hormones, characterized by estrogen-positive (ER-plus), progesterone-positive (PgR-plus), or both.
    ER-positive has important prognosmical value and is the main predictive indicator of endocrine therapy (ET) sensitivity.
    , however, up to 50% of patients with ER-plus breast cancer do not respond to ET treatment.
    , the search for more accurate predictive biomarkers is imminent.
    previous studies have shown that transcription of PgR is directly regulated by estrogen.
    , PgR levels rise only when ER functions properly and estrogen is present.
    these limitations also led to inconsistent results in clinical studies that assessed the value of PgR in predicting ET effects.
    clearly, there is a need for better ways to determine the level and functional status of tumor ER and PgR in order to better identify the patients most likely to benefit from ET treatment.
    hypothesization that short-lived esodiol therapy would only raise PgR levels in tumors with functional ER.
    respondents and non-respondents in this prospective Phase 2 single-center one-arm trial (NCT02455453), the researchers reported a correlation between the patient's response to ET the day before and after estradiol treatment and the intake of progesterone-like (21- .18F) fluorofuran dethylaminate, FFNP).
    Overall survival results In 43 post-menoanthorum women with ER-plus breast cancer, the researchers found that only 28 subjects (respondents) who had a clinical benefit from ET had an increased intake of tumor FFNP, while 15 patients who did not have a clinical benefit (no respondents) had an increase in FFNP intake, indicating 100 percent sensitivity and specificity of the change.
    further studies have shown that subjects who responded survived significantly longer.
    , the results show that changes in tumor FFNP intake after esodiol therapy can highly predict the response of women with ER-plus breast cancer to ET treatment.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.